2026 China Biotechnology Innovation Conference opens in Suzhou

China News Service, Suzhou, November 1 (Reporter Chang Mucheng) The 2026 China Biotechnology Innovation Conference with the theme of "Digital Intelligence Empowers Medicine and Innovation Leads Health" officially opened in Suzhou on the morning of the 1st. The conference will set up theme reports, special sub-sessions, closed seminars and other sections to conduct in-depth discussions on hot topics such as the integration of AI and life sciences, biomanufacturing, and new biomedical technologies.

Fan Bo, deputy secretary of the Jiangsu Provincial Party Committee and secretary of the Suzhou Municipal Party Committee, introduced in his speech that biomedicine is the core track that Suzhou has been cultivating for 20 years. It has now built a full-chain industrial ecosystem from R&D, clinical, manufacturing to application. Suzhou will continue to build a first-class cooperation platform, cultivate a first-class industrial ecology, create a first-class business environment, and work with experts and enterprises in the field of biomedicine at home and abroad to build an innovation highland for the biomedicine industry.

The conference invited Jin Li, academician of the Chinese Academy of Sciences and president of Fudan University, to serve as chairman of the academic committee. Jin Li pointed out in his speech that the essence of biotechnology competition is the competition of underlying tools, scientific data and standard rules. At present, my country's high-end sequencing equipment, core reagents, basic algorithms, biological databases and other bases are still lacking. He suggested strengthening data infrastructure, developing forward-looking plans, respecting the laws of scientific research, and accelerating the realization of high-level self-reliance and self-reliance in biotechnology.

In his speech, Zheng Zhongwei, Supervisor of the Department of Science, Technology and Education of the National Health Commission, suggested that original innovation should be the driving force to stimulate new impetus for the development of the health and health industry; full-chain collaboration should be the guarantee to accelerate the cultivation of new health and health productivity; system construction should be the basis to strengthen health and safety governance; and the talent team should be the support to create the main force of health and health innovation.

Suzhou Industrial Park has deeply promoted open innovation in the entire biopharmaceutical industry chain, and its comprehensive industrial competitiveness has continued to rank first among similar parks in the country. Pan Yu, director of the Science and Technology Innovation Committee of Suzhou Industrial Park, said in an interview that the next step is to work with leading companies to jointly build major platforms such as the National Biopharmaceutical Technology Innovation Center, concentrate resources on key common technologies, and strive to produce a number of landmark results with major influence.